Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion type Assertion NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_head.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion description "[The PC-3 tumor cell line has an elevated expression of GRP-Rs (2.5 x 10(5)/cell), whereas LNCaP--a prostate cancer metastatic cell line representing the early androgen-sensitive stage of prostate cancer--and DU145--an androgen-insensitive metastatic line--express lower receptor numbers (5.9 x 10(3) and 1.2 x 10(4)/cell, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_provenance.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion evidence source_evidence_literature NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_provenance.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion SIO_000772 19910427 NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_provenance.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion wasDerivedFrom befree-20150227 NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_provenance.
- NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_assertion wasGeneratedBy ECO_0000203 NP878454.RAtA4ZYypCoS3CjF1QqBnijx44OjxK7MOk6LWlNyvMouk130_provenance.